Compare PLXS & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLXS | STVN |
|---|---|---|
| Founded | 1979 | 1949 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Electrical Products | Containers/Packaging |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.4B |
| IPO Year | N/A | N/A |
| Metric | PLXS | STVN |
|---|---|---|
| Price | $196.67 | $15.88 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $194.00 | $23.75 |
| AVG Volume (30 Days) | 426.4K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.26 | $8.42 |
| Revenue Next Year | $8.18 | $9.61 |
| P/E Ratio | $30.46 | ★ $26.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $103.43 | $13.91 |
| 52 Week High | $211.84 | $28.00 |
| Indicator | PLXS | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 40.83 |
| Support Level | $193.49 | $15.43 |
| Resistance Level | $211.84 | $16.69 |
| Average True Range (ATR) | 10.07 | 0.99 |
| MACD | -1.15 | 0.19 |
| Stochastic Oscillator | 60.44 | 60.60 |
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.